ArticleBMC biology2026
Dynamin inhibitor dynasore modulates longitudinal bone growth in a hormetic manner.
Article in BMC biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLongitudinal bone growth occurs via endochondral ossification, involving a complex interplay of chondrocyte proliferation, differentiation, and matrix remodeling. As with all mammalian cells, chondrocytes require dynamin for mitochondrial fission, to shuttle vesicles from the Golgi apparatus, and for both clathrin- and caveolin-mediated endocytosis. Here, we aimed to test the functions of dynamin on bone growth. To do so, we applied dynasore-a small molecule that is a reversible dynamin inhibitor-to mouse metatarsal bones cultured ex vivo. We assessed gross changes using bone length measurements combined with EdU detection, immunostaining, super-resolution microscopy and transmission electron microscopy.
resultsDynasore induced a dose-dependent hormetic effect on bone elongation: while high concentrations (220 µM) impaired growth and abolished chondrocyte proliferation, low-dose treatment (40 µM) significantly increased longitudinal bone growth. Histological analysis demonstrated that low dose dynasore augmented epiphyseal cartilage expansion and matrix accumulation, while reducing chondrocyte proliferation. Immunostaining indicated that 40 µM dynasore preserved collagen type X synthesis, activated mTORC1 signaling, and blocked autophagy, based on SQSTM1 accumulation. Low dose dynasore treatment expanded the thickness of the filamentous actin layer at the plasma membrane and deepened endocytic pits containing collagen fibril-like electron-dense extracellular structures, indicating that impaired cartilage remodeling was associated with growth-associated matrix accumulation. Finally, the use of a structurally unrelated dynamin inhibitor, dynole, indicated that the effects of dynasore were partially mediated by its actions on dynamin.
conclusionsDynasore exerts hormetic effects on epiphyseal chondrocytes, wherein low doses stimulate bone elongation, and high doses impair chondrocyte function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.